BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, Gibson MK, Stoller RG, Zeh HJ, Bahary N. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108:236-241. [PMID: 23955427 DOI: 10.1002/jso.23392] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Lombardi P, Silvestri S, Marino D, Santarelli M, Campra D, De Paolis P, Aglietta M, Leone F. “Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria. Critical Reviews in Oncology/Hematology 2019;133:17-24. [DOI: 10.1016/j.critrevonc.2018.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801-810. [PMID: 27160474 DOI: 10.1016/s1470-2045(16)00172-8] [Cited by in Crossref: 416] [Cited by in F6Publishing: 193] [Article Influence: 69.3] [Reference Citation Analysis]
3 Buc E, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? World J Surg Oncol 2014;12:347. [PMID: 25407113 DOI: 10.1186/1477-7819-12-347] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
4 Fukahori M, Miwa K, Murotani K, Naito Y, Ushijima T, Sakaue T, Tanaka T, Nagasu S, Suga H, Kakuma T, Okabe Y, Torimura T. A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Medicine (Baltimore) 2021;100:e26052. [PMID: 34011119 DOI: 10.1097/MD.0000000000026052] [Reference Citation Analysis]
5 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
6 Wo JY, Niemierko A, Ryan DP, Blaszkowsky LS, Clark JW, Kwak EL, Lillemoe KD, Drapek LN, Zhu AX, Allen JN, Faris JE, Murphy JE, Nipp R, Fernandez-Del Castillo C, Ferrone CR, Hong TS. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol 2018;41:656-61. [PMID: 28134673 DOI: 10.1097/COC.0000000000000349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kozak GM, Epstein JD, Deshmukh SP, Scott BB, Keith SW, Lavu H, Yeo CJ, Winter JM. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. J Gastrointest Surg 2018;22:288-94. [PMID: 29139084 DOI: 10.1007/s11605-017-3595-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Luu AM, Herzog T, Hoehn P, Reinacher-Schick A, Munding J, Uhl W, Braumann C. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:E9-E12. [PMID: 29755782 DOI: 10.21037/jgo.2018.01.07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
9 Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS One 2019;14:e0215409. [PMID: 31026288 DOI: 10.1371/journal.pone.0215409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Mikulic D, Mrzljak A. Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy. World J Clin Cases 2021; 9(20): 5398-5407 [PMID: 34307593 DOI: 10.12998/wjcc.v9.i20.5398] [Reference Citation Analysis]
11 Hank T, Strobel O. Conversion Surgery for Advanced Pancreatic Cancer. J Clin Med 2019;8:E1945. [PMID: 31718103 DOI: 10.3390/jcm8111945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
12 Luu AM, Hoehn P, Vogel SR, Reinacher-Schick A, Munding J, Uhl W, Braumann C. Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. Visc Med 2019;35:387-91. [PMID: 31934588 DOI: 10.1159/000497827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas 2020;49:393-407. [PMID: 32132518 DOI: 10.1097/MPA.0000000000001507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
14 Lekka K, Tzitzi E, Giakoustidis A, Papadopoulos V, Giakoustidis D. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg 2019;23:97-108. [PMID: 31225409 DOI: 10.14701/ahbps.2019.23.2.97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Okubo Y, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer 2021;21:1319. [PMID: 34886831 DOI: 10.1186/s12885-021-09069-9] [Reference Citation Analysis]
16 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
17 Felder SI, Ramanathan R, Russo AE, Jimenez-Rodriguez RM, Hogg ME, Zureikat AH, Strong VE, Zeh HJ, Weiser MR. Robotic gastrointestinal surgery. Curr Probl Surg. 2018;55:198-246. [PMID: 30470267 DOI: 10.1067/j.cpsurg.2018.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Stonko DP, He J, Zheng L, Blair AB. A contemporary evidence basis for neoadjuvant chemotherapy in upfront resectable pancreatic adenocarcinoma: a systematic review of the literature. Journal of Pancreatology 2020;3:12-20. [DOI: 10.1097/jp9.0000000000000037] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 N Kalimuthu S, Serra S, Dhani N, Hafezi-Bakhtiari S, Szentgyorgyi E, Vajpeyi R, Chetty R. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study. J Clin Pathol 2017;70:237-43. [PMID: 27681847 DOI: 10.1136/jclinpath-2016-203947] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
20 Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:982-8. [PMID: 30603116 DOI: 10.21037/jgo.2018.04.03] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Shen ZT, Zhou H, Li AM, Ji XQ, Jiang CC, Yuan X, Li B, Zhu XX, Huang GC. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. J Cancer Res Clin Oncol 2020;146:417-28. [PMID: 31667573 DOI: 10.1007/s00432-019-03066-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
22 Rangelova E, Wefer A, Persson S, Valente R, Tanaka K, Orsini N, Segersvärd R, Arnelo U, Del Chiaro M. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. Annals of Surgery 2021;273:579-86. [DOI: 10.1097/sla.0000000000003301] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
23 Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, Chang HM, Lee SS, Park DH, Song TJ, Seo DW. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget. 2017;8:46337-46347. [PMID: 28564637 DOI: 10.18632/oncotarget.17940] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
24 Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54:979-985. [PMID: 25734581 DOI: 10.3109/0284186x.2015.1004367] [Cited by in Crossref: 112] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis]
25 di Sebastiano P, Grottola T, di Mola FF. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy. Updates Surg. 2016;68:235-239. [PMID: 27629483 DOI: 10.1007/s13304-016-0392-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Adamu M, Nitschke P, Petrov P, Rentsch A, Distler M, Reissfelder C, Welsch T, Saeger H, Weitz J, Rahbari NN. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology 2018;18:585-91. [DOI: 10.1016/j.pan.2018.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E, Barni S. FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies. Pancreas 2015;44:515-21. [DOI: 10.1097/mpa.0000000000000314] [Cited by in Crossref: 126] [Cited by in F6Publishing: 46] [Article Influence: 18.0] [Reference Citation Analysis]
28 Kim JS, Park JY, Choi M, Joo DJ, Hwang HK, Lee WJ, Kang CM. Pancreaticoduodenectomy with combined hepatic artery and portal vein resection after laparoscopic division of pancreaticosplenic ligament due to FOLFIRINOX-induced hepatic toxicity related secondary hypersplenism. Ann Hepatobiliary Pancreat Surg 2021;25:307-12. [PMID: 34053937 DOI: 10.14701/ahbps.2021.25.2.307] [Reference Citation Analysis]
29 Valsecchi ME, Díaz-Cantón E, de la Vega M, Littman SJ. Recent treatment advances and novel therapies in pancreas cancer: a review. J Gastrointest Cancer 2014;45:190-201. [PMID: 24343588 DOI: 10.1007/s12029-013-9561-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
30 Kirkpatrick S, Gillies G, Underwood P, Cioffi J, Trevino JG, Hughes SJ. Biliary intervention rates during neoadjuvant therapy for adenocarcinoma of the pancreatic head. HPB (Oxford) 2021;23:1196-200. [PMID: 33388244 DOI: 10.1016/j.hpb.2020.11.1147] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Buwenge M, Cellini F, Silvestris N, Cilla S, Deodato F, Macchia G, Mattiucci GC, Valentini V, Morganti AG. Robotic radiosurgery in pancreatic cancer: A systematic review. World J Gastroenterol 2015; 21(31): 9420-9429 [PMID: 26309369 DOI: 10.3748/wjg.v21.i31.9420] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
32 Sadot E, Doussot A, O'Reilly EM, Lowery MA, Goodman KA, Do RK, Tang LH, Gönen M, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Ann Surg Oncol 2015;22:3512-21. [PMID: 26065868 DOI: 10.1245/s10434-015-4647-4] [Cited by in Crossref: 92] [Cited by in F6Publishing: 90] [Article Influence: 13.1] [Reference Citation Analysis]
33 Mariette C, Brouquet A, Tzanis D, Laurenzi A, de la Rochefordière A, Mariani P, Piessen G, Sa Cunha A, Penna C. What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer? Journal of Visceral Surgery 2017;154:185-95. [DOI: 10.1016/j.jviscsurg.2017.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
34 Khushman M, Dempsey N, Cudris Maldonado J, Loaiza-bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CD, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Rocha Lima CM, Hosein PJ. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology 2015;15:667-73. [DOI: 10.1016/j.pan.2015.08.010] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
35 Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med 2019;19:149-57. [PMID: 30498929 DOI: 10.1007/s10238-018-0540-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Rombouts S, Walma M, Vogel JA, Rijssen Lv, Wilmink J, Mohammad NH, Santvoort Hv, Molenaar IQ, Besselink MG Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. American Society of Clinical Oncology Annual Meeting. 2016;suppl: abstr 4115. [PMID: 27370653 DOI: 10.1245/s10434-016-5373-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 13.2] [Reference Citation Analysis]
37 Russo S, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol. 2016;12:669-685. [PMID: 26880384 DOI: 10.2217/fon.15.335] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
38 Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, Urba S, Zeh HJ, Katz MH. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2541-2556. [PMID: 27247221 DOI: 10.1200/jco.2016.67.5553] [Cited by in Crossref: 195] [Cited by in F6Publishing: 80] [Article Influence: 32.5] [Reference Citation Analysis]
39 Palmarocchi MC, Balzarotti Canger RC, Saletti P. Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncol Lett 2017;13:4445-52. [PMID: 28588713 DOI: 10.3892/ol.2017.6026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 Papadatos-Pastos D, Thillai K, Rabbie R, Ross P, Sarker D. FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer. Expert Rev Anticancer Ther. 2014;14:1115-1125. [PMID: 25204327 DOI: 10.1586/14737140.2014.957188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
41 Pollom EL, Koong AC, Ko AH. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:741-59. [PMID: 26226908 DOI: 10.1016/j.hoc.2015.04.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
42 Nipp RD, Zanconato A, Zheng H, Ferrone CR, Lillemoe KD, Wo JY, Hong TS, Clark JW, Ryan DP, Fernández-del Castillo C. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas 2017;46:183-9. [DOI: 10.1097/mpa.0000000000000731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
43 Toesca DAS, Koong AJ, Poultsides GA, Visser BC, Haraldsdottir S, Koong AC, Chang DT. Management of Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2018;100:1155-74. [PMID: 29722658 DOI: 10.1016/j.ijrobp.2017.12.287] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
44 Attard JA, Farrugia A, Pathanki A, Roberts KJ, Dasari B, Isaac J, Ma YT, Chatzizacharias NA. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. Pancreas 2020;49:1264-75. [PMID: 33122513 DOI: 10.1097/MPA.0000000000001694] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Mahmood J, Alexander AA, Samanta S, Kamlapurkar S, Singh P, Saeed A, Carrier F, Cao X, Shukla HD, Vujaskovic Z. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice. Cancers (Basel) 2020;12:E1015. [PMID: 32326142 DOI: 10.3390/cancers12041015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Beane JD, Griffin KF, Levy EB, Pandalai P, Wood B, Abi-Jaoudeh N, Beresnev T, Shutack Y, Webb CC, Avital I, Rudloff U. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study. Invest New Drugs 2015;33:109-18. [PMID: 25236592 DOI: 10.1007/s10637-014-0157-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
47 Kiriukova M, de la Iglesia Garcia D, Panic N, Bozhychko M, Avci B, Maisonneuve P, de-Madaria E, Capurso G, Sandru V. Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer. Front Med (Lausanne) 2020;7:495. [PMID: 33015088 DOI: 10.3389/fmed.2020.00495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
48 Coleman O, Henry M, McVey G, Clynes M, Moriarty M, Meleady P. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. Expert Rev Proteomics 2016;13:383-94. [PMID: 26985644 DOI: 10.1586/14789450.2016.1167601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
49 Tang K, Lu W, Qin W, Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016;16:28-37. [PMID: 26687001 DOI: 10.1016/j.pan.2015.11.007] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 12.7] [Reference Citation Analysis]
50 Carotenuto P, Amato F, Lampis A, Rae C, Hedayat S, Previdi MC, Zito D, Raj M, Guzzardo V, Sclafani F, Lanese A, Parisi C, Vicentini C, Said-Huntingford I, Hahne JC, Hallsworth A, Kirkin V, Young K, Begum R, Wotherspoon A, Kouvelakis K, Azevedo SX, Michalarea V, Upstill-Goddard R, Rao S, Watkins D, Starling N, Sadanandam A, Chang DK, Biankin AV, Jamieson NB, Scarpa A, Cunningham D, Chau I, Workman P, Fassan M, Valeri N, Braconi C. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nat Commun 2021;12:6738. [PMID: 34795259 DOI: 10.1038/s41467-021-27099-6] [Reference Citation Analysis]
51 Tol JA, Eshuis WJ, Besselink MG, van Gulik TM, Busch OR, Gouma DJ. Non-radical resection versus bypass procedure for pancreatic cancer - a consecutive series and systematic review. Eur J Surg Oncol 2015;41:220-7. [PMID: 25511567 DOI: 10.1016/j.ejso.2014.11.041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
52 Okada K, Kawai M, Hirono S, Satoi S, Yanagimoto H, Ioka T, Miyazawa M, Shimizu A, Kitahata Y, Yamaue H. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol 2016;78:719-26. [PMID: 27501851 DOI: 10.1007/s00280-016-3121-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
53 Li D, O’Reilly EM. Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. Surg Oncol Clin N Am. 2016;25:311-326. [PMID: 27013366 DOI: 10.1016/j.soc.2015.11.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
54 Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016;151:e161137. [PMID: 27275632 DOI: 10.1001/jamasurg.2016.1137] [Cited by in Crossref: 225] [Cited by in F6Publishing: 197] [Article Influence: 37.5] [Reference Citation Analysis]
55 Khachfe HH, Habib JR, Nassour I, Al Harthi S, Jamali FR. Borderline Resectable and Locally Advanced Pancreatic Cancers: A Review of Definitions, Diagnostics, Strategies for Treatment, and Future Directions. Pancreas 2021;50:1243-9. [PMID: 34860806 DOI: 10.1097/MPA.0000000000001924] [Reference Citation Analysis]
56 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
57 Wei Q, Yu W, Rosati LM, Herman JM. Advances of stereotactic body radiotherapy in pancreatic cancer. Chin J Cancer Res. 2015;27:349-357. [PMID: 26361404 DOI: 10.3978/j.issn.1000-9604.2015.04.12] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
58 Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017;152:1048-1056. [PMID: 28700784 DOI: 10.1001/jamasurg.2017.2227] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
59 Huguet F, Mukherjee S, Javle M. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Clin Oncol (R Coll Radiol). 2014;26:560-568. [PMID: 25001636 DOI: 10.1016/j.clon.2014.06.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
60 Bolm L, Mueller K, May K, Sondermann S, Petrova E, Lapshyn H, Honselmann KC, Bausch D, Zemskov S, Bronsert P, Keck T, Deichmann S, Wellner UF. Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients-Proposal of a New Simplified Borderline Resectability Definition. Cancers (Basel) 2020;12:E882. [PMID: 32260453 DOI: 10.3390/cancers12040882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Chapman BC, Gleisner A, Rigg D, Meguid C, Goodman K, Brauer B, Gajdos C, Schulick RD, Edil BH, McCarter MD. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. J Surg Oncol. 2018;117:1073-1083. [PMID: 29448308 DOI: 10.1002/jso.25004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
62 Neofytou K, Giakoustidis A, Smyth EC, Cunningham D, Mudan S. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy. J Surg Oncol. 2015;111:768-770. [PMID: 25556724 DOI: 10.1002/jso.23867] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
63 Nipp RD, Ryan DP. Predicting a response to FOLFIRINOX in pancreatic cancer. J Natl Cancer Inst 2015;107:djv175. [PMID: 26025325 DOI: 10.1093/jnci/djv175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17:651-662. [PMID: 27055731 DOI: 10.1016/s1470-2045(16)00078-4] [Cited by in Crossref: 308] [Cited by in F6Publishing: 209] [Article Influence: 51.3] [Reference Citation Analysis]
65 Blair AB, Sorber R, Rozich NS, Burkhart RA. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas 2019;48:973-84. [DOI: 10.1097/mpa.0000000000001376] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Choi YH, Lee SH, You MS, Shin BS, Paik WH, Ryu JK, Kim YT, Kwon W, Jang JY, Kim SW. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Gut Liver 2021;15:315-23. [PMID: 32235008 DOI: 10.5009/gnl19182] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Heger U, Sun H, Hinz U, Klaiber U, Tanaka M, Liu B, Sachsenmaier M, Springfeld C, Michalski CW, Büchler MW, Hackert T. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. HPB (Oxford) 2020;22:224-32. [PMID: 31375338 DOI: 10.1016/j.hpb.2019.06.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
68 Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, Kendrick ML, Nagorney DM, Smoot RL, Farnell MB, Truty MJ. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Journal of the American College of Surgeons 2016;223:52-65. [DOI: 10.1016/j.jamcollsurg.2016.02.009] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
69 Blair AB, Groot VP, He J. Lessons learned by features of pancreatic ductal adenocarcinoma and its tumor microenvironment. Ann Transl Med 2019;7:S9. [PMID: 31032290 DOI: 10.21037/atm.2019.01.32] [Reference Citation Analysis]
70 Coveler AL, Herman JM, Simeone DM, Chiorean EG. Localized Pancreatic Cancer: Multidisciplinary Management. Am Soc Clin Oncol Educ Book 2016;35:e217-26. [PMID: 27249726 DOI: 10.1200/EDBK_160827] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
71 Martin RCG 2nd. Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation. J Surg Oncol 2017;116:35-45. [PMID: 28475814 DOI: 10.1002/jso.24640] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
72 Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019;49:894-906. [PMID: 30949842 DOI: 10.1007/s00595-019-01804-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
73 Martin RC. Management of Locally Advanced Pancreatic Cancer. Surgical Clinics of North America 2016;96:1371-89. [DOI: 10.1016/j.suc.2016.07.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
74 Colbert LE, Hall WA, Nickleach D, Switchenko J, Kooby DA, Liu Y, Gillespie T, Lipscomb J, Kauh J, Landry JC. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Cancer 2014;120:499-506. [PMID: 24390739 DOI: 10.1002/cncr.28530] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
75 Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Int J Radiat Oncol Biol Phys 2017;97:313-22. [PMID: 28068239 DOI: 10.1016/j.ijrobp.2016.10.030] [Cited by in Crossref: 78] [Cited by in F6Publishing: 59] [Article Influence: 13.0] [Reference Citation Analysis]
76 Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jäger D, Büchler MW, Debus J. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. Ann Surg Oncol 2014;21:2801-7. [PMID: 24916745 DOI: 10.1245/s10434-014-3607-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
77 Gisel A, Valvano M, El Idrissi IG, Nardulli P, Azzariti A, Carrieri A, Contino M, Colabufo NA. miRNAs for the detection of multidrug resistance: overview and perspectives. Molecules 2014;19:5611-23. [PMID: 24786846 DOI: 10.3390/molecules19055611] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
78 Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, Baines AT, Graves LM. Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth. SLAS Discov 2018;23:850-61. [PMID: 29742358 DOI: 10.1177/2472555218773045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
79 Alemi F, Alseidi A, Scott Helton W, Rocha FG. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Curr Probl Surg 2015;52:362-98. [PMID: 26363649 DOI: 10.1067/j.cpsurg.2015.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Natsume S, Shimizu Y, Senda Y, Hijioka S, Matsuo K, Ito S, Komori K, Abe T, Hara K. Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate. Surg Today 2019;49:670-7. [PMID: 30730003 DOI: 10.1007/s00595-019-01776-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
81 Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Nishiwada S, Tamamoto T, Nishiofuku H, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbecks Arch Surg 2015;400:477-85. [PMID: 25929828 DOI: 10.1007/s00423-015-1304-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
82 Kays JK, Shahda S, Stanley M, Bell TM, O'Neill BH, Kohli MD, Couch ME, Koniaris LG, Zimmers TA. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9:673-684. [PMID: 29978562 DOI: 10.1002/jcsm.12307] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 11.5] [Reference Citation Analysis]
83 Khattab A, Patruni S, Abel S, Hasan S, Ludmir EB, Finley G, Monga D, Wegner RE, Verma V. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. J Gastrointest Oncol 2019;10:918-27. [PMID: 31602330 DOI: 10.21037/jgo.2019.07.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Obaid G, Bano S, Mallidi S, Broekgaarden M, Kuriakose J, Silber Z, Bulin AL, Wang Y, Mai Z, Jin W, Simeone D, Hasan T. Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia? Nano Lett 2019;19:7573-87. [PMID: 31518145 DOI: 10.1021/acs.nanolett.9b00859] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
85 Blair AB, Rosati LM, Rezaee N, Gemenetzis G, Zheng L, Hruban RH, Cameron JL, Weiss MJ, Wolfgang CL, Herman JM, He J. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Surgery. 2018;163:1090-1096. [PMID: 29395234 DOI: 10.1016/j.surg.2017.11.027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
86 Mohammed S, II GVB, Fisher WE. Pancreatic cancer: Advances in treatment. World J Gastroenterol 2014; 20(28): 9354-9360 [PMID: 25071330 DOI: 10.3748/wjg.v20.i28.9354] [Cited by in F6Publishing: 71] [Reference Citation Analysis]
87 Itchins M, Arena J, Nahm CB, Rabindran J, Kim S, Gibbs E, Bergamin S, Chua TC, Gill AJ, Maher R, Diakos C, Wong M, Mittal A, Hruby G, Kneebone A, Pavlakis N, Samra J, Clarke S. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. Eur J Surg Oncol 2017;43:1711-7. [PMID: 28688722 DOI: 10.1016/j.ejso.2017.06.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
88 Jung JP, Zenati MS, Hamad A, Hogg ME, Simmons RL, Zureikat AH, Zeh HJ, Boone BA. Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma? HPB (Oxford) 2019;21:679-86. [PMID: 30501987 DOI: 10.1016/j.hpb.2018.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 He J, Page AJ, Weiss M, Wolfgang CL, Herman JM, Pawlik TM. Management of borderline and locally advanced pancreatic cancer: Where do we stand? World J Gastroenterol 2014; 20(9): 2255-2266 [PMID: 24605025 DOI: 10.3748/wjg.v20.i9.2255] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
90 Hackert T, Ulrich A, Büchler MW. Borderline resectable pancreatic cancer. Cancer Lett 2016;375:231-7. [PMID: 26970276 DOI: 10.1016/j.canlet.2016.02.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
91 Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng SP, Samra J, Shakeshaft J, Goldstein D, Nguyen N, Goodman KA, Chang DT, Kneebone A. Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Pract Radiat Oncol 2020;10:e136-46. [PMID: 31761541 DOI: 10.1016/j.prro.2019.07.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
92 Rosati LM, Kumar R, Herman JM. Integration of Stereotactic Body Radiation Therapy into the Multidisciplinary Management of Pancreatic Cancer. Semin Radiat Oncol 2017;27:256-67. [PMID: 28577833 DOI: 10.1016/j.semradonc.2017.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
93 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
94 Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I. FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. Clinical Colorectal Cancer 2014;13:232-8. [DOI: 10.1016/j.clcc.2014.09.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
95 Suker M, Nuyttens JJ, Groot Koerkamp B, Eskens FALM, van Eijck CHJ. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. J Surg Oncol 2018;118:1021-6. [PMID: 30259526 DOI: 10.1002/jso.25233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
96 Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. BMC Cancer 2016;16:786. [PMID: 27724927 DOI: 10.1186/s12885-016-2821-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
97 Chen Z, Lv Y, Li H, Diao R, Zhou J, Yu T. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. Medicine (Baltimore) 2021;100:e24068. [PMID: 33546009 DOI: 10.1097/MD.0000000000024068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Moningi S, Marciscano AE, Rosati LM, Ng SK, Teboh Forbang R, Jackson J, Chang DT, Koong AC, Herman JM. Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Rev Anticancer Ther 2014;14:1461-75. [PMID: 25183386 DOI: 10.1586/14737140.2014.952286] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
99 Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Ann Surg Oncol 2015;22 Suppl 3:S1212-20. [PMID: 26350368 DOI: 10.1245/s10434-015-4851-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
100 Jimenez-rodriguez RM, Weiser MR. In Brief. Current Problems in Surgery 2018;55:194-5. [DOI: 10.1067/j.cpsurg.2018.08.001] [Reference Citation Analysis]
101 Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, Gajdos C, McCarter MD. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine (Baltimore). 2014;93:e198. [PMID: 25501072 DOI: 10.1097/md.0000000000000198] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
102 Hashemi-Sadraei N, Gbolahan OB, Salfity H, O'Neil B, House MG, Shahda S. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol 2018;41:982-5. [PMID: 28968257 DOI: 10.1097/COC.0000000000000409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
103 Kurosawa J, Tawada K, Mikata R, Ishihara T, Tsuyuguchi T, Saito M, Shimofusa R, Yoshitomi H, Ohtsuka M, Miyazaki M, Yokosuka O. Prognostic relevance of apparent diffusion coefficient obtained by diffusion-weighted MRI in pancreatic cancer: Role of DW-MRI in Pancreatic Cancer. J Magn Reson Imaging 2015;42:1532-7. [DOI: 10.1002/jmri.24939] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
104 Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst 2019;111:782-94. [PMID: 31086963 DOI: 10.1093/jnci/djz073] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 38.5] [Reference Citation Analysis]
105 Tchelebi L, Zaorsky N, Mackley H. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines 2018;6:E7. [PMID: 29301352 DOI: 10.3390/biomedicines6010007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
106 Amodeo S, Masi A, Melis M, Ryan T, Hochster HS, Cohen DJ, Chandra A, Pachter HL, Newman E. Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. J Gastrointest Oncol 2018;9:922-35. [PMID: 30505595 DOI: 10.21037/jgo.2017.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
107 Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15:183. [PMID: 29017581 DOI: 10.1186/s12957-017-1240-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
108 Wang L, Cheng CS, Chen L, Chen Z. Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. Cancer Manag Res 2018;10:1907-18. [PMID: 30013397 DOI: 10.2147/CMAR.S167103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Luu AM, Braumann C, Belyaev O, Janot-Matuschek M, Rudolf H, Praktiknjo M, Uhl W. Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head. Hepatobiliary Pancreat Dis Int 2021;20:271-8. [PMID: 33349608 DOI: 10.1016/j.hbpd.2020.12.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Shaib WL, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, Landry J, El-Rayes BF. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Oncologist 2016;21:178-87. [PMID: 26834159 DOI: 10.1634/theoncologist.2015-0316] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
111 Han S, Choi SH, Choi DW, Heo JS, Han IW, Park DJ, Ryu Y. Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer. Minerva Chir 2020;75:15-24. [PMID: 31115240 DOI: 10.23736/S0026-4733.19.07958-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Blakaj A, Stein SM, Khan SA, Johung KL. Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol 2018;9:1027-36. [PMID: 30603121 DOI: 10.21037/jgo.2018.03.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Buanes TA. Pancreatic cancer-improved care achievable. World J Gastroenterol 2014; 20(30): 10405-10418 [PMID: 25132756 DOI: 10.3748/wjg.v20.i30.10405] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
114 Tsvetkova EV, Asmis TR. Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here? Curr Oncol. 2014;21:e650-e657. [PMID: 25089113 DOI: 10.3747/co.21.2006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
115 Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM, Moore A, Espinoza D, Gebski V, Yip S, Chu J, Kneebone A, Goldstein D. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer 2021;21:936. [PMID: 34412605 DOI: 10.1186/s12885-021-08666-y] [Reference Citation Analysis]
116 Ocuin LM, Miller-Ocuin JL, Novak SM, Bartlett DL, Marsh JW, Tsung A, Lee KK, Hogg ME, Zeh HJ, Zureikat AH. Robotic and open distal pancreatectomy with celiac axis resection for locally advanced pancreatic body tumors: a single institutional assessment of perioperative outcomes and survival. HPB (Oxford) 2016;18:835-42. [PMID: 27506992 DOI: 10.1016/j.hpb.2016.05.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
117 Yang A, O'Reilly EM. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. Expert Rev Gastroenterol Hepatol 2015;9:585-601. [PMID: 25686370 DOI: 10.1586/17474124.2015.1012496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Lakatos G, Petranyi A, Szűcs A, Nehéz L, Harsanyi L, Hegyi P, Bodoky G. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. Pathol Oncol Res 2017;23:753-9. [PMID: 28062950 DOI: 10.1007/s12253-016-0176-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
119 Turner K, Levi Sandri GB, Boucher E, Hénno S, Le Prisé E, Meunier B, Boudjema K, Sulpice L. Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case. Clin Res Hepatol Gastroenterol 2015;39:e29-31. [PMID: 25288453 DOI: 10.1016/j.clinre.2014.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
120 Tchelebi LT, Lehrer EJ, Trifiletti DM, Sharma NK, Gusani NJ, Crane CH, Zaorsky NG. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis. Cancer 2020;126:2120-31. [PMID: 32125712 DOI: 10.1002/cncr.32756] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
121 Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016;114:587-596. [PMID: 27444658 DOI: 10.1002/jso.24375] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
122 Bednar F, Zenati MS, Steve J, Winters S, Ocuin LM, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Ann Surg Oncol 2017;24:1406-13. [PMID: 27896518 DOI: 10.1245/s10434-016-5707-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
123 Sasaki T, Isayama H, Aoki T, Tanaka M, Hamada T, Nakai Y, Sakamoto Y, Hasegawa K, Morikawa T, Fukayama M. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. Pancreas. 2014;43:972-974. [PMID: 25010709 DOI: 10.1097/mpa.0000000000000139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
124 Cellini F, Arcelli A, Simoni N, Caravatta L, Buwenge M, Calabrese A, Brunetti O, Genovesi D, Mazzarotto R, Deodato F, Mattiucci GC, Silvestris N, Valentini V, Morganti AG. Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers (Basel). 2020;12. [PMID: 32610592 DOI: 10.3390/cancers12071729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]